1. Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis
- Author
-
Amr Abbass, Ahmed Ghalwash, Heba Omar, Mohamed El Kassas, Mohamed Eltabbakh, Ahmad Sweedy, Sameera Ezzat, Hassan Hamdy, Shimaa Afify, Mohamed Salaheldin, Dalia Omran, Rasha Farghaly, Helmy Elshazly, Nermeen Abdeen, Marwa Tahoon, Mohamed Alboraie, and Mohammed Emadeldeen
- Subjects
Liver Cirrhosis ,Ledipasvir ,medicine.medical_specialty ,Pyrrolidines ,Daclatasvir ,Genotype ,Sustained Virologic Response ,Sofosbuvir ,Hepatitis C virus ,Population ,Hepacivirus ,medicine.disease_cause ,Antiviral Agents ,Severity of Illness Index ,End Stage Liver Disease ,Liver disease ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,education ,Retrospective Studies ,Fluorenes ,education.field_of_study ,Hepatology ,business.industry ,Imidazoles ,Gastroenterology ,Valine ,Hepatitis C ,Hepatitis C, Chronic ,medicine.disease ,Decompensated cirrhosis ,Treatment Outcome ,chemistry ,Benzimidazoles ,Drug Therapy, Combination ,Carbamates ,business ,medicine.drug - Abstract
BACKGROUND Hepatitis C virus (HCV)-related decompensated cirrhosis is a severe life-threatening illness. The safety of direct-acting antivirals (DAAs) has opened a gate of hope for that subgroup of patients who were previously contraindicated for interferon therapy. OBJECTIVE We aimed at the investigation of the safety and efficacy of different DAAs regimens in the treatment of HCV-related decompensated cirrhosis patients, to determine sustained virological response (SVR)12 rates and to analyze the factors associated with response. METHODS A retrospective, single-center study including HCV-related decompensated cirrhosis patients who received DAAs. Demographic, laboratory and clinical data were analyzed. The SVR12 rate was the primary outcome measure. Secondary outcomes included the predictors of response, changes in the baseline model for end-stage liver disease and child-turcotte-pugh (CTP) scores, and fibroindices (APRI and fibrosis-4 index) at 12 weeks after treatment. RESULTS In total, 145 eligible patients (141 with CTP class B and 4 with class C) were enrolled in this study. SVR12 was achieved by 88.06% (118/134) of efficacy population on different DAAs regimens, Treatment was discontinued in 11 patients because of severe side effects without any deaths. Younger age showed a significant positive association with SVR12. CONCLUSIONS DAAs can be used for the treatment of HCV-related decompensated liver disease, with acceptable SVR12 rates and safety profiles.
- Published
- 2021